Abstract: Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or --C(C.sub.1-6 alkyl)NOH or --C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.

Abstract: A method of treatment of bacterial infections in humans which comprises administering to a patient one or two unit dosages per day of a compound of formula (I): ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically acceptable salting ion or a pharmaceutically acceptable ester-forming radical, andR.sup.2 is hydrogen, a pharmaceutically acceptable salting ion or an in vivo hydrolyzable ester-forming radical.

Abstract: A compound of formula (I), and salts thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy group;R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, C.sub.1-7 acyl, amino, C.sub.1-7 acyl amino, aminocarbonyl or aminosulphone optionally substituted by one or two C.sub.1-6 alkyl groups; C.sub.1-6 alkyl-SO.sub.n wherein n is 1 or 2; or nitro;R.sub.4 is hydrogen or C.sub.1-6 alkyl;R.sub.5 is C.sub.1-6 alkyl or a group --(CH.sub.2).sub.s R.sub.6 wherein s is 1 or 2 and R.sub.6 is C.sub.3-8 cycloalkyl or phenyl, which phenyl may optionally be substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-4 alkoxy, CF.sub.3 and halogen;n is 0 to 3;p is 3 to 6; andr plus s is 2 to 5; may be used for the treatment of disorders of the gastro-intestinal function.

Abstract: A process for the preparation of an antibacterially active compound of the formula (I): ##STR1## and salts and esters thereof wherein R.sup.1 and R.sup.2 independently are hydrogen or an organic group, and R.sup.3 is an organic group bonded via a carbon atom to the sulphur atom, which comprises reacting a compound of the formula (II): ##STR2## wherein R.sup.4 is an organic group different to R.sup.3 and R.sup.a is hydrogen or a carboxy-blocking group, with a thiol R.sup.3 SH or reactive derivative thereof. In addition certain compounds within the formula (II) are novel and useful antibacterial agents in their own right.

Abstract: An intramammary composition containing a siloxane elastomer with incorporated antibacterial agent. The composition is of sufficiently low viscosity to facilitate application to the teat of a cow via the streak canal, and the composition remains sufficiently elastic to enable it to remain in place during the dry period and to allow it to be readily milked-out at the onset of lactation. The composition is useful in reducing mammary infections in cattle during their dry period and is compatible with conventional mastitis treatments at the end of lactation.

Abstract: Compounds of formula (I): ##STR1## wherein X is methoxy or ethoxy, Y is amino or C.sub.1-6 alkanoylamino, Z is hydrogen, chloro or bromo and R.sub.1 is methyl, chloro or fluoro, have anti-psychotic activity, and are useful in the treatment of CNS disorders.

Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein: X is CH.sub.2, O, S or NR.sub.4 wherein R.sub.4 is hydrogen or C.sub.1-4 alkyl;one of Y and Z is NR.sub.5 and the other is CR.sub.6 R.sub.7 wherein R.sub.5 is hydrogen, C.sub.1-4 alkyl or C.sub.1-4 acyl and R.sub.6 and R.sub.7 are either both hydrogen or together form an oxo group;R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-7 cycloalkenyl or C.sub.1-4 alkyl substituted by C.sub.2-7 alkenyl, C.sub.2-7 alkynyl, C.sub.3-7 cycloalkyl, amino optionally substituted by one or two C.sub.1-4 alkyl or by C.sub.4-6 polymethylene optionally containing an oxygen atom or by phenyl C.sub.1-4 alkyl optionally substituted in the phenyl ring by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or trifluoromethyl; andR.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, hydroxy, C.sub.1-4 alkyl C.sub.

Abstract: A 1-aza[3.2.0]bicycloheptan-2-carboxylic acid or salt or ester thereof having a substituent at position 7 of the formula:.dbd.CR.sup.1 R.sup.2wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen or an organic group.

Abstract: The present invention provides a compound of the formula (I): ##STR1## and pharmaceutically acceptable salts and in-vivo hydrolysable esters thereof wherein R.sup.1 is carboxy, R.sup.2 is hydrogen or carboxy, R.sup.3 is hydrogen, acyl, C.sub.1-6 akyl or C.sub.2-6 alkenyl, any of such R.sup.3 groups being optionally substituted, and R.sup.4 is an amino or protected amino group.Processes for the preparation of these compounds are described as is their use in the treatment of bacterial infection.

Abstract: Compounds of the formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is hydroxy, C.sub.1-4 alkoxy or an in-vivo hydrolysable acyloxy group:R.sub.2 is hydrogen, C.sub.1-4 alkyl, hydroxy, C.sub.1-4 alkoxy or an in-vivo hydrolysable acyloxy group;R.sub.4 is benzofuryl, benzothienyl, indolyl, quinolyl, isoquinolyl,2,3-dihydrobenzofuryl, 2,3-dihydrobenzylthienyl or 2,3-dihydroindolyl optionally substituted by one or two substituents selected from C.sub.1-4 alkoxy, hydroxy or acyloxy, trifluoromethyl, halogen or nitro; andA is a bond or C.sub.1-6 alkylene,a process for their preparation, and pharmaceutical compositions containing them.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: n, p and q independently are 0 to 2;R.sub.5 is hydrogen or C.sub.1-6 alkyl;R.sub.6 is C.sub.1-7 alkyl or a group --(CH.sub.2).sub.s R.sub.7 where s is 0 to 2 and R.sub.7 is a C.sub.3-8 cycloalkyl group, or a group --(CH.sub.2).sub.t R.sub.8 where t is 1 or 2 and R.sub.8 is C.sub.2-5 alkenyl or a phenyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and halogen, or a thienyl group;R.sub.12 is C.sub.1-6 alkylsulphonyl;and eitherR.sub.1 is C.sub.1-6 alkoxy or C.sub.1-6 alkylthio; and one of R.sub.2 and R.sub.11 is hydrogen and the other is C.sub.1-6 alkoxy, C.sub.1-6 alkyl or hydroxy; or R.sub.1 and R.sub.2 together are C.sub.1-3 alkylenedioxy; and R.sub.11 is hydrogen, halogen, CF.sub.3, C.sub.1-6 alkoxy,hydroxy, nitro, C.sub.1-7 acyl, amino, C.sub.1-7 acylamino, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl, C.sub.

Abstract: The preparation and use of 6,.alpha.-methoxy-6,.beta.-[2-(2-methylphenoxycarbonyl)-2-(thien-3-yl) acetamido] penicillanic acid of formula (II): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

Abstract: Compounds of formula (I): ##STR1## wherein: one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino, or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino, or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano or --C(alkyl)NOH or --C(alkyl)NNH.sub.2, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms;one of R.sub.3 and R.sub.4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R.sub.3 and R.sub.

Abstract: There is provided a process for the preparation of an enantiomer of a compound of formula (I) which process comprises separation thereof from a mixture of diastereoisomers of a compound of the formula (I): ##STR1## wherein R is acetyl, .alpha.-hydroxyethyl or a protected derivative thereof, and R.sup.1 and R.sup.2 are substituted or unsubstituted hydrocarbon groups, or are joined so as to form a carbocyclic or heterocyclic ring; at least one of R.sup.1 and R.sup.2 containing a chiral center, such that the enantiomer can be separated thereby; and R.sup.3 and R.sup.4 are independently hydrogen or an organic group bonded via a carbon atom to the tetrahydro-oxazine ring, or R.sup.3 and R.sup.4 are joined so as to form together with the carbon atom to which they are attached an optionally substituted C.sub.3-7 cycloalkyl or optionally substituted heterocyclyl ring.The enantiomer is of use in the preparation of optically active carbapenem antibiotics.

Abstract: Compounds of formula (I): ##STR1## wherein Y is halogen,R.sup.1 is hydrogen, a salt forming radical, alkyl or aralkyl,have antibacterial and/or antimycoplasmal activity.

Abstract: An inhalent allergen composition comprises an inhalent allergen and a saponin adjuvant. The inhalent allergen may be an extract of a grass pollen, such as rye grass, or a weed, such as ragweed. The saponin adjuvant may be an extract from the bark of the tree Quillaja Molina, and known as Quil-A.

Abstract: Compounds of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein m is 0 to 3;n is 1 to 5;R.sub.1 is hydrogen, or C.sub.1-6 alkyl;R.sub.2 is hydrogen, C.sub.1-4 alkyl, --(CH.sub.2).sub.p --NH.sub.2wherein p is 1 to 4, or --NHCOR, wherein R.sub.5 is C.sub.1-4 alkyl;R.sub.3 is hydrogen or C.sub.1-6 alkyl;R.sub.4 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or CF.sub.3 ; and X is CH.sub.2 or S.having useful pharmacological activity, compositions containing them, and a process for their preparation.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: a is 1 to 3;b is 0 to 2;c is 2 to 4;d is 1 to 5;X is sulphur, oxygen or --CH.sub.2 --;Y is oxygen, sulphur, NR.sub.4 or CHR.sub.5 wherein R.sub.4 is hydrogen, C.sub.1-4 alkyl, NO.sub.2 or CN, C.sub.1-4 alkylsulphonyl or phenylsulphonyl optionally substituted in the phenyl moiety by one or two substituents selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, fluorine, chlorine or bromine, and R.sub.5 is NO.sub.2, C.sub.1-4 alkylsulphonyl or optionally substituted phenylsulphonyl as defined for R.sub.4 ;R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-4 alkyl, or C.sub.3-6 cycloalkyl; or R.sub.1 and R.sub.2 taken together with the nitrogen to which they are attached represent a pyrrolidino or piperidino ring;R.sub.6 and R.sub.7 are independently hydrogen or C.sub.

Abstract: The present invention provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in-vivo hydrolyzable ester thereof wherein R.sup.1 is a hydrogen atom, an .alpha.-sulphonato-oxyethyl group, an .alpha.-sulphonato-oxypropyl group or is a group CR.sup.3 R.sup.4 R.sup.5 wherein R.sup.3 is a hydrogen atom or a hydroxy group; R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl group; and R.sup.5 is a hydrogen atom or a C.sub.1-6 alkyl group, a benzyl group, a phenyl group or is joined to R.sup.4 to form together with the carbon atom to which they are joined a carbocyclic ring of 5 to 7 carbon atoms; R.sup.2 is a pyrimidinyl group substituted by one two or three groups selected from nitro, halo, amino or substituted amino, and in addition may be optionally substituted by one or two C.sub.1-6 alkyl groups as the degree of substitution permits; and x is zero or one.These compounds are antibacterial agents. Their preparation and use are described.

Abstract: The stability of an oily intramammary formulation containing a suspension of a solid clavulanic acid salt is improved by incorporation therein of molecular sieve powder.